Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer.
BAP1 and therapy
asbestos
mesothelioma
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
revised:
22
11
2023
received:
25
07
2023
accepted:
15
01
2024
medline:
9
3
2024
pubmed:
9
3
2024
entrez:
9
3
2024
Statut:
aheadofprint
Résumé
Mesothelioma is a type of late-onset cancer that develops in cells covering the outer surface of organs. Although it can affect the peritoneum, heart, or testicles, it mainly targets the lining of the lungs, making pleural mesothelioma (PMe) the most common and widely studied mesothelioma type. PMe is caused by exposure to fibres of asbestos, which when inhaled leads to inflammation and scarring of the pleura. Despite the ban on asbestos by most Western countries, the incidence of PMe is on the rise, also facilitated by a lack of specific symptomatology and diagnostic methods. Therapeutic options are also limited to mainly palliative care, making this disease untreatable. Here we present an overview of biological aspects underlying PMe by listing genetic and molecular mechanisms behind its onset, aggressive nature, and fast-paced progression. To this end, we report on the role of deubiquitinase BRCA1-associated protein-1 (BAP1), a tumour suppressor gene with a widely acknowledged role in the corrupted signalling and metabolism of PMe. This review aims to enhance our understanding of this devastating malignancy and propel efforts for its investigation.
Identifiants
pubmed: 38459714
doi: 10.1002/1878-0261.13591
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Gruppo Italiano Mesotelioma G.I.Me Charity
ID : 2019
Organisme : H2020 European Research Council
ID : COG2018-819600_FIRM
Organisme : Fondation ARC pour la Recherche sur le Cancer
ID : ARCLEADER2022020004901
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : MFAG21903
Informations de copyright
© 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Mutsaers SE, Herrick SE. Mesothelial cells. In: Geoffrey JL, Steven DS, editors. Encyclopedia of Respiratory Medicine, Four-Volume Set. Oxford: Academic Press; 2006. p. 47-52.
Valenciano AC, Rizzi TE. Abdominal, thoracic, and pericardial effusions. In: Valenciano AC, Cowell RL, editors. Cowell and Tyler's Diagnostic Cytology and Hematology of the Dog and Cat. St. Louis, MO: Elsevier Mosby; 2020. p. 229-246.
Mutsaers SE. The mesothelial cell. Int J Biochem Cell Biol. 2004;36(1):9-16. https://doi.org/10.1016/S1357-2725(03)00242-5
Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603.
Odgerel CO, Takahashi K, Sorahan T, Driscoll T, Fitzmaurice C, Yoko-o M, et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017;74(12):851-858. https://doi.org/10.1136/oemed-2017-104298
Tischoff I, Tannapfel A. Mesotheliom. Pathologe. 2017;38(6):547-560. https://doi.org/10.1007/s00292-017-0364-z
D'Agostino HP, Edens MA. Physiology, Pleural Fluid. Treasure Island, FL: StatPearls Publishing; 2019.
Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J. 1998;12:4-981.
What is pleural mesothelioma? Full overview & what to expect. Accessed 30 Jun 2020. https://www.asbestos.com/mesothelioma/pleural/
Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg. 2004;78(5):1774-1776. https://doi.org/10.1016/j.athoracsur.2004.05.007
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243-1260.
Van Schil PE, Opitz I, Weder W, De Laet C, Domen A, Lauwers P, et al. Multimodal management of malignant pleural mesothelioma: where are we today? Eur Respir J. 2014;44(3):754-764. https://doi.org/10.1183/09031936.00207213
Kim KC, Vo HP. Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor. J Thorac Dis. 2016;8(6):E379-E384. https://doi.org/10.21037/jtd.2016.03.92
Borczuk AC, Chan JKC, Cooper WA, Dacic S, Kerr KM, Lantuejoul S, et al. Thoracic Tumours. Vol. 2 (Dilani L, Valerie AW, Beiko W, lan AC, editors). International Agency for Pesearch on Cancer (lABC); 2021. https://publications.iarc.fr/581. Accessed 25 Sep 2023.
Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2018;142(1):89-108. https://doi.org/10.5858/arpa.2017-0124-RA
Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):543-549. https://doi.org/10.21037/tlcr.2018.07.05
Nakano T. Systemic treatment of malignant pleural mesothelioma. Gan To Kagaku Ryoho. 2017;44(13):2041-2047. https://doi.org/10.1097/cco.0000000000000053
Zhang W, Wu X, Wu L, Zhang W, Zhao X. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Ann Transl Med. 2015;3(13):182. https://doi.org/10.3978/j.issn.2305-5839.2015.07.03
Kharazmi E, Chen T, Fallah M, Sundquist K, Sundquist J, Albin M, et al. Familial risk of pleural mesothelioma increased drastically in certain occupations: a nationwide prospective cohort study. Eur J Cancer. 2018;103:1-6. https://doi.org/10.1016/j.ejca.2018.07.139
Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397-408. https://doi.org/10.1016/S0140-6736(05)67025-0
Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA. 2006;103(38):14128-14133. https://doi.org/10.1073/pnas.0604544103
Wagner GR, Lemen R. Asbestos. In: Heggenhougen HK, editor. International Encyclopedia of Public Health. Boston, MA: Elsevier Inc.; 2008. p. 238-245.
Rudd R. Asbestos and the lung. Medicine. 2008;36(5):261-264. https://doi.org/10.1016/j.mpmed.2008.02.001
Landrigan PJ, Nicholson WJ, Suzuki Y, Ladou J. The hazards of chrysotile asbestos: a critical review. Ind Health. 1999;37(3):271-280. https://doi.org/10.2486/indhealth.37.271
Habashi F. Asbestos. In: Jürgen Buschow KH, Cahn RW, Flemings MC, Ilschner B, Kramer EJ, Mahajan S, et al., editors. Encyclopedia of Materials: Science and Technology. 2nd ed. Amsterdam: Elsevier; 2002. p. 1-5.
Wagner GR, Lemen RA. Asbestos. In: Quah SR, editor. International Encyclopedia of Public Health. Amsterdam: Elsevier Inc.; 2016. p. 176-182.
Chen M, Wang H, Zhang J, Yu C, Liu W, Xu Y. Distribution of asbestos enterprises and asbestosis cases - China, 1997-2019. China CDC Wkly. 2020;2(18):305-309. https://doi.org/10.46234/ccdcw2020.078
Korda RJ, Clements MS, Armstrong BK, Law HD, Guiver T, Anderson PR, et al. Risk of cancer associated with residential exposure to asbestos insulation: a whole-population cohort study. Lancet Public Health. 2017;2(11):e522-e528. https://doi.org/10.1016/S2468-2667(17)30192-5
Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global asbestos disaster. Int J Environ Res Public Health. 2018;15(5):1000. https://doi.org/10.3390/ijerph15051000
Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev. 1997;6:162-166.
Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005;92(3):587-593. https://doi.org/10.1038/sj.bjc.6602307
Marsili D, Terracini B, Santana VS, Ramos-Bonilla J, Pasetto R, Mazzeo A, et al. Prevention of asbestos-related disease in countries currently using asbestos. Int J Environ Res Public Health. 2016;13(5):494. https://doi.org/10.3390/ijerph13050494
Heintz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci USA. 1993;90(8):3299-3303. https://doi.org/10.1073/pnas.90.8.3299
Jaurand MC, Fleury-Feith J. Pathogenesis of malignant pleural mesothelioma. Respirology. 2005;10(1):2-8. https://doi.org/10.1111/j.1440-1843.2005.00694.x
Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand MC. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med. 2012;136(3):277-293. https://doi.org/10.5858/arpa.2011-0215-RA
Røe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer. 2010;67(1):57-68. https://doi.org/10.1016/j.lungcan.2009.03.016
Chernova T, Murphy FA, Galavotti S, Sun XM, Powley IR, Grosso S, et al. Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a (Ink4a/Arf). Curr Biol. 2017;27(21):3302-3314.e6. https://doi.org/10.1016/j.cub.2017.09.007
Lushchak VI. Free radicals, reactive oxygen species, oxidative stress and its classification. Chem Biol Interact. 2014;224:164-175. https://doi.org/10.1016/j.cbi.2014.10.016
Toyokuni S. Mechanisms of asbestos-induced carcinogenesis. Nagoya J Med Sci. 2009;71:1-10.
Ottaviani MF, Venturi F, Pokhrel MR, Schmutz T, Bossmann SH. Physicochemical studies on the adsorption properties of asbestos: 2. An EPR and fluorescence study on the adsorption of pyrene. J Colloid Interface Sci. 2001;238(2):371-380. https://doi.org/10.1006/jcis.2001.7529
Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34(7):1413-1419. https://doi.org/10.1093/carcin/bgt166
Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase Cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res. 1996;56:5334-5338.
Zanella CL, Timblin CR, Cummins A, Jung M, Goldberg J, Raabe R, et al. Asbestos-induced phosphorylation of epidermal growth factor receptor is linked to c-Fos and apoptosis. Am J Physiol. 1999;277:L684-L693.
Heintz NH, Janssen-Heininger YMW, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010;42(2):133-139. https://doi.org/10.1165/rcmb.2009-0206TR
Ameyar M, Wisniewska M, Weitzman JB. A role for AP-1 in apoptosis: the case for and against. Biochimie. 2003;85(8):747-752. https://doi.org/10.1016/j.biochi.2003.09.006
Below JE, Cox NJ, Fukagawa NK, Hirvonen A, Testa JR. Factors that impact susceptibility to fiber-induced health effects. J Toxicol Environ Health B Crit Rev. 2011;14(1-4):246-266. https://doi.org/10.1080/10937404.2011.556052
Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007;7(2):147-154. https://doi.org/10.1038/nrc2068
Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol. 1999;180(2):150-157. https://doi.org/10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H
Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668-672. https://doi.org/10.1038/ng.855
Cheung M, Testa JR. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res. 2017;6(3):270-278. https://doi.org/10.21037/tlcr.2017.05.03
Ferru A, Fromont G, Gibelin H, Guilhot J, Savagner F, Tourani JM, et al. The status of CDKN2A alpha (p16INK4A) and beta (p14 ARF) transcripts in thyroid tumour progression. Br J Cancer. 2006;95(12):1670-1677. https://doi.org/10.1038/sj.bjc.6603479
Esposito V, Baldi A, De Luca A, Claudio PP, Signoriello G, Bolognese A, et al. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res. 1997;17(1B):733-736.
Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92(6):713-723. https://doi.org/10.1016/S0092-8674(00)81400-2
Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol. 2009;1(5):a001883. https://doi.org/10.1101/cshperspect.a001883
Li P, Zhang X, Gu L, Zhou J, Deng D. P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib. PLoS One. 2019;14(10):e0223084. https://doi.org/10.1371/journal.pone.0223084
Stamenkovic I, Yu Q. Merlin, a “magic” linker between the extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci. 2010;11(6):471-484. https://doi.org/10.2174/138920310791824011
Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer. 2009;64(2):140-147. https://doi.org/10.1016/j.lungcan.2008.08.014
Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene. 2012;31(49):5117-5122. https://doi.org/10.1038/onc.2012.5
Yokoyama T. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis. 2008;29:2139-2146.
Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642-655. https://doi.org/10.1016/j.cell.2009.01.035
Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-a miRNA microarray analysis. Genes Chromosomes Cancer. 2009;48(7):615-623. https://doi.org/10.1002/gcc.20669
Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol. 2010;42(3):312-319. https://doi.org/10.1165/rcmb.2009-0060OC
Birnie KA, Prêle CM, Thompson PJ, Badrian B, Mutsaers SE. Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma. Oncotarget. 2017;8(44):78193-78207. https://doi.org/10.18632/oncotarget.20409
De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, et al. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci Rep. 2017;7:3140. https://doi.org/10.1038/s41598-017-02694-0
Ivanov SV, Goparaju CMV, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem. 2010;285(30):22809-22817. https://doi.org/10.1074/jbc.M110.100354
Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(20):3589-3594. https://doi.org/10.1242/jcs.051011
Grosso S, Marini A, Gyuraszova K, Voorde JV, Sfakianos A, Garland GD, et al. The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nat Commun. 2021;12(1):1-17. https://doi.org/10.1038/s41467-021-25173-7
Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960-976. https://doi.org/10.1016/j.cell.2017.02.004
James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, et al. NF2/Merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29(15):4250-4261. https://doi.org/10.1128/mcb.01581-08
Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, de Rienzo A, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005;24(40):6080-6089. https://doi.org/10.1038/sj.onc.1208744
Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg. 2008;33(3):502-506. https://doi.org/10.1016/j.ejcts.2007.09.045
Nastase A, Mandal A, Lu SK, Anbunathan H, Morris-Rosendahl D, Zhang YZ, et al. Integrated genomics point to immune vulnerabilities in pleural mesothelioma. Sci Rep. 2021;11(1):1-15. https://doi.org/10.1038/s41598-021-98414-w
Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127-150. https://doi.org/10.1146/annurev.pathol.4.110807.092311
Graziani I, Eliasz S, De Marco MA, Chen Y, Pass HI, De May RM, et al. Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res. 2008;68(23):9678-9685. https://doi.org/10.1158/0008-5472.CAN-08-0969
Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem. 2002;277(23):20336-20342. https://doi.org/10.1074/jbc.M111899200
Blum W, Schwaller B. Calretinin is essential for mesothelioma cell growth/survival in vitro: a potential new target for malignant mesothelioma therapy? Int J Cancer. 2013;133(9):2077-2088. https://doi.org/10.1002/ijc.28218
Wörthmüller J, Blum W, Pecze L, Salicio V, Schwaller B. Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway. Oncotarget. 2018;9(91):36256-36272. https://doi.org/10.18632/oncotarget.26332
Saydan N, Salicio V, Cappelli-Gotzos B, Gotzos V. Expression of calretinin in human mesothelioma cell lines and cell cycle analysis by flow cytometry. Anticancer Res. 2001;21(1A):181-188.
CALB2 calbindin 2 [Homo sapiens (human)] - Gene - NCBI. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=794. Accessed 5 Sep 2020.
Billing-Marczak K, Buzanska L, Winsky L, Nowotny M, Rudka T, Isaacs K, et al. AP2-like cis element is required for calretinin gene promoter activity in cells of neuronal phenotype differentiated from multipotent human cell line DEV. Biochim Biophys Acta Gene Struct Expr. 2002;1577(3):412-420. https://doi.org/10.1016/S0167-4781(02)00443-8
Billing-Marczak K, Ziemińska E, Leśniak W, Łazarewicz JW, Kuźnicki J. Calretinin gene promoter activity is differently regulated in neurons and cancer cells. Role of AP2-like cis element and zinc ions. Biochim Biophys Acta Gene Struct Expr. 2004;1678(1):14-21. https://doi.org/10.1016/j.bbaexp.2004.01.004
Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, et al. Function of the c-met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):1-14. https://doi.org/10.1186/s12943-018-0796-y
Tolnay E, Kuhnen C, Wiethege T, König JE, Voss B, Müller KM. Hepatocyte growth factor/scatter factor and its receptor c-met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol. 1998;124(6):291-296. https://doi.org/10.1007/s004320050171
Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, et al. Inhibition of the met receptor in mesothelioma. Clin Cancer Res. 2005;11(22):8122-8130. https://doi.org/10.1158/1078-0432.CCR-05-1191
Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, et al. Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res. 2007;13(19):5942-5951. https://doi.org/10.1158/1078-0432.CCR-07-0536
Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA. 2006;103(27):10397-10402. https://doi.org/10.1073/pnas.0604008103
Heckman CA, Mehew JW, Boxer LM. NF-kB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene. 2002;21:3898-3908. https://doi.org/10.1038/sj/onc/1205483
Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, et al. Wnt pathway activation in mesothelioma: evidence of dishevelled overexpression and transcriptional activity of β-catenin. Cancer Res. 2003;63(15):4547-4551.
BAP1 BRCA1 associated protein 1 [Homo sapiens (human)] - Gene - NCBI. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=8314. Accessed 12 Jun 2023.
BAP1 - Ubiquitin carboxyl-terminal hydrolase BAP1 - Homo sapiens (Human) - BAP1 gene & protein. https://www.uniprot.org/uniprot/Q92560. Accessed 13 Jun 2023.
BAP1 (BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase)). http://atlasgeneticsoncology.org/Genes/BAP1ID755ch3p21.html. Accessed 16 Jun 2023.
Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16(9):1097-1112. https://doi.org/10.1038/sj.onc.1201861
Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y, Livingston DM. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev. 2006;20(1):34-46. https://doi.org/10.1101/gad.1381306
Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M, et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 2009;69(1):111-119. https://doi.org/10.1158/0008-5472.CAN-08-3355
Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J, Sui G, et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol. 2010;30(21):5071-5085. https://doi.org/10.1128/mcb.00396-10
Campagne A, Lee MK, Zielinski D, Michaud A, le Corre S, Dingli F, et al. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation. Nat Commun. 2019;10(1):1-15. https://doi.org/10.1038/s41467-018-08255-x
Lee HS, Lee SA, Hur SK, Seo JW, Kwon J. Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis. Nat Commun. 2014;5(1):1-14. https://doi.org/10.1038/ncomms6128
Baymaz HI, Fournier A, Laget S, Ji Z, Jansen PWTC, Smits AH, et al. MBD5 and MBD6 interact with the human PR-DUB complex through their methyl-CpG-binding domain. Proteomics. 2014;14(19):2179-2189. https://doi.org/10.1002/pmic.201400013
Farquhar N, Thornton S, Coupland SE, Coulson JM, Sacco JJ, Krishna Y, et al. Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res. 2018;4(1):26-38. https://doi.org/10.1002/cjp2.86
Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402-429. https://doi.org/10.3322/caac.21572
Pastorino Yyhpmemnip S. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol. 2018;36:3485-3494.
Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76-81. https://doi.org/10.1093/carcin/bgu227
Liu-Smith F, Lu Y. Opposite roles of BAP1 in overall survival of uveal melanoma and cutaneous melanoma. J Clin Med. 2020;9(2):411. https://doi.org/10.3390/jcm9020411
Ewens KG, Lalonde E, Richards-Yutz J, Shields CL, Ganguly A. Comparison of germline versus somatic BAP1 mutations for risk of metastasis in uveal melanoma 11 medical and health sciences 1112 oncology and carcinogenesis. BMC Cancer. 2018;18(1):1172. https://doi.org/10.1186/s12885-018-5079-x
Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci USA. 2019;116:9008-9013. https://doi.org/10.1073/pnas.1821510116
Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012;103(5):868-874. https://doi.org/10.1111/j.1349-7006.2012.02223.x
Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, et al. BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int J Mol Sci. 2019;20(2). https://doi.org/10.3390/IJMS20020429
Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, et al. BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and Pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study. J Thorac Oncol. 2022;17(7):921-930. https://doi.org/10.1016/J.JTHO.2022.04.008
Terrié E, Coronas V, Constantin B. Role of the calcium toolkit in cancer stem cells. Cell Calcium. 2019;80:141-151. https://doi.org/10.1016/j.ceca.2019.05.001
Sun C, Shui B, Zhao W, Liu H, Li W, Lee JC, et al. Central role of IP3R2-mediated Ca2+ oscillation in self-renewal of liver cancer stem cells elucidated by high-signal ER sensor. Cell Death Dis. 2019;10(6):1-13. https://doi.org/10.1038/s41419-019-1613-2
Inai K. Pathology of mesothelioma. Environ Health Prev Med. 2008;13:60-64. https://doi.org/10.1007/s12199-007-0017-6
Porpodis K, Zarogoulidis P, Boutsikou E, Papaioannou A, Machairiotis N, Tsakiridis K, et al. Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis. 2013;5(SUPPL.4):S397-S406. https://doi.org/10.3978/j.issn.2072-1439.2013.08.08
Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int. 2008;58(2):75-83. https://doi.org/10.1111/j.1440-1827.2007.02193.x
Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19(4):514-523. https://doi.org/10.1038/modpathol.3800534
Naso JR, Tsuji S, Churg A. HEG1 is a highly specific and sensitive marker of epithelioid malignant mesothelioma. Am J Surg Pathol. 2020;44:1143-1148. https://doi.org/10.1097/PAS.0000000000001469
Chapel DB, Husain AN, Krausz T. Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations. Mod Pathol. 2019;32:376-386. https://doi.org/10.1038/s41379-018-0159-7
Churg A, Hwang H, Tan L, Qing G, Taher A, Tong A, et al. Malignant mesothelioma in situ. Histopathology. 2018;72(6):1033-1038. https://doi.org/10.1111/HIS.13468
Klebe S, Nakatani Y, Dobra K, Butnor KJ, Roden AC, Nicholson AG, et al. The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. Pathology. 2021;53(4):446-453. https://doi.org/10.1016/J.PATHOL.2020.12.005
Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer. 2015;113(6):963-969. https://doi.org/10.1038/bjc.2015.286
Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541-1549. https://doi.org/10.1200/JCO.2011.39.6671
Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, et al. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer. 2017;17(1):386. https://doi.org/10.1186/s12885-017-3375-5
Gee GV, Koestler DC, Christensen BC, Sugarbaker DJ, Ugolini D, Ivaldi GP, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 2010;127(12):2859-2869. https://doi.org/10.1002/ijc.25285
Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, et al. A diagnostic assay based on MicroRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn. 2010;12(6):771-779. https://doi.org/10.2353/jmoldx.2010.090169
Ortiz-Quintero B. Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. Cell Prolif. 2016;49(3):281-303. https://doi.org/10.1111/cpr.12262
Moretti G, Aretini P, Lessi F, Mazzanti CM, Ak G, Metintaş M, et al. Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: a feasibility study. Cancers (Basel). 2021;13(10):2445. https://doi.org/10.3390/CANCERS13102445/S1
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513-10518. https://doi.org/10.1073/pnas.0804549105
Bononi I, Comar M, Puozzo A, Stendardo M, Boschetto P, Orecchia S, et al. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers. Oncotarget. 2016;7(50):82700-82711. https://doi.org/10.18632/oncotarget.12408
Tsim S, Alexander L, Kelly C, Shaw A, Hinsley S, Clark S, et al. Serum proteomics and plasma Fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. J Thorac Oncol. 2021;16(10):1705-1717. https://doi.org/10.1016/j.jtho.2021.05.018
Baldini EH, Richards WG, Gill RR, Goodman BM, Winfrey OK, Eisen HM, et al. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2015;149(5):1374-1381. https://doi.org/10.1016/j.jtcvs.2014.10.128
Zhai Z, Ruan J, Zheng Y, Xiang D, Li N, Hu J, et al. Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Netw Open. 2021;4(8):e2120360. https://doi.org/10.1001/JAMANETWORKOPEN.2021.20360
Cancer statistics review, 1975-2017 - SEER statistics. https://seer.cancer.gov/archive/csr/1975_2017/. Accessed 23 Nov 2022.
Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(Suppl 2):S304-S310. https://doi.org/10.21037/jtd.2017.10.19
Ricciardi S, Cardillo G, Zirafa CC, Carleo F, Facciolo F, Fontanini G, et al. Surgery for malignant pleural mesothelioma: an international guidelines review. J Thorac Dis. 2018;10(Suppl 2):S285-S292. https://doi.org/10.21037/jtd.2017.10.16
Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763-772. https://doi.org/10.1016/S1470-2045(11)70149-8
Rodríguez Panadero F. Diagnóstico y tratamiento del mesotelioma pleural maligno. Arch Bronconeumol. 2015;51(4):177-184. https://doi.org/10.1016/j.arbres.2014.06.005
Scherpereel A, Scherpereel A, Opitz I, Psallidas I, Glatzer M, Rigau D, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. https://doi.org/10.1183/13993003.00953-2019
Lim E, Darlison L, Edwards J, Elliott D, Fennell DA, Popat S, et al. Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma On behalf of MARS 2 Trialists. BMJ Open. 2020;10:e038892. https://doi.org/10.1136/bmjopen-2020-038892
Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother Oncol. 2006;80(1):13-18. https://doi.org/10.1016/j.radonc.2006.06.002
Rosenzweig KE, Giraud P. Radiothérapie des mésothéliomes malins pleuraux. Cancer/Radiotherapie. 2017;21(1):73-76. https://doi.org/10.1016/j.canrad.2016.09.009
Chi A, Liao Z, Nguyen NP, Howe C, Gomez D, Jang SY, et al. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2011;6(6):1132-1141. https://doi.org/10.1097/JTO.0b013e3182199819
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. https://doi.org/10.1200/JCO.2003.11.136
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405-1414.
Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):1-12. https://doi.org/10.1186/S13046-019-1259-Z
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. https://doi.org/10.1016/S0140-6736(20)32714-8
Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, et al. Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open. 2022;5(3):e221490. https://doi.org/10.1001/jamanetworkopen.2022.1490
Messori A, Trippoli S. Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials. J Chemother. 2023;35:158-162. https://doi.org/10.1080/1120009X.2022.2061183
Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, et al. A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern. JTO Clin Res Rep. 2022;3(3):100280. https://doi.org/10.1016/J.JTOCRR.2022.100280
Yang L, Cao X, Li N, Zheng B, Liu M, Cai H. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Ther Adv Med Oncol. 2022;14:17588359221116604. https://doi.org/10.1177/17588359221116604
Ye ZM, Tang ZQ, Xu Z, Zhou Q, Li H. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma. Front Public Health. 2022;10:947375.
Munck C, Mordon SR, Scherpereel A, Porte H, Dhalluin X, Betrouni N. Intrapleural photodynamic therapy for mesothelioma: what place and which future? Ann Thorac Surg. 2015;99(6):2237-2245. https://doi.org/10.1016/j.athoracsur.2014.12.077
van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386-1396. https://doi.org/10.1016/S1470-2045(17)30621-6
Ur Rehman SI, Haaris SM. Oncolytic viral therapy. J Pak Med Assoc. 2017;67(4):658. https://doi.org/10.1097/01.cot.0000669692.29645.ac
Pease DF, Kratzke RA. Oncolytic viral therapy for mesothelioma. Front Oncol. 2017;7:179. https://doi.org/10.3389/fonc.2017.00179
Acuna SA, Ottolino-Perry K, Çako B, Tang N, Angarita FA, McCart JA. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21(7):2259-2266. https://doi.org/10.1245/s10434-014-3651-4